{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:42:42Z","timestamp":1777916562572,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T00:00:00Z","timestamp":1506297600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00535-017-1391-5","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T08:16:09Z","timestamp":1506327369000},"page":"557-565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis"],"prefix":"10.1007","volume":"53","author":[{"given":"Kazuaki","family":"Chayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyasu","family":"Karino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiiku","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomofumi","family":"Atarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunamasa","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Yoshiji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Seike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Burroughs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Redman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Pugatch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tami J.","family":"Pilot-Matias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preethi","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajneet K.","family":"Oberoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wangang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,25]]},"reference":[{"issue":"3","key":"1391_CR1","first-page":"378","volume":"9","author":"H Bennett","year":"2015","unstructured":"Bennett H, Waser N, Johnston K, et al. A review of the burden of hepatitis C virus infection in China, Japan. South Korea and Taiwan. Hepatol Int. 2015;9(3):378\u201390.","journal-title":"South Korea and Taiwan. Hepatol Int"},{"issue":"Suppl 2","key":"1391_CR2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1478-3231.2011.02540.x","volume":"31","author":"W Sievert","year":"2011","unstructured":"Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31(Suppl 2):61\u201380.","journal-title":"Liver Int"},{"issue":"4","key":"1391_CR3","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333\u201342.","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"1391_CR4","first-page":"S65","volume":"15","author":"GG Liu","year":"2012","unstructured":"Liu GG, DiBonaventura M, Yuan Y, et al. The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan. Value Health. 2012;15(1 Suppl):S65\u201371.","journal-title":"Value Health"},{"issue":"3","key":"1391_CR5","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1440-1746.2009.05789.x","volume":"24","author":"ML Yu","year":"2009","unstructured":"Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009;24(3):336\u201345.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"1391_CR6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","volume":"112","author":"G Fattovich","year":"1997","unstructured":"Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463\u201372.","journal-title":"Gastroenterology"},{"issue":"1","key":"1391_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2000-9506","volume":"20","author":"A Wasley","year":"2000","unstructured":"Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20(1):1\u201316.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"1391_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00535-012-0714-9","volume":"48","author":"K Chayama","year":"2013","unstructured":"Chayama K, Hayes CN, Ohishi W, et al. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 2013;48(1):1\u201312.","journal-title":"J Gastroenterol"},{"issue":"4","key":"1391_CR9","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep.27972","volume":"62","author":"H Kumada","year":"2015","unstructured":"Kumada H, Chayama K, Rodrigues L Jr, et al. Randomized phase 3 trial of ombitasvir\/paritaprevir\/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62(4):1037\u201346.","journal-title":"Hepatology"},{"issue":"6","key":"1391_CR10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","volume":"15","author":"M Mizokami","year":"2015","unstructured":"Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12\u00a0weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645\u201353.","journal-title":"Lancet Infect Dis"},{"key":"1391_CR11","unstructured":"JSH HCV Treatment Guidelines (2017)."},{"issue":"2","key":"1391_CR12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/hepr.12645","volume":"46","author":"Y Asahina","year":"2016","unstructured":"Asahina Y, Izumi N, Hiromitsu K, et al. JSH Guidelines for the Management of Hepatitis C Virus Infection: a 2016 update for genotype 1 and 2. Hepatol Res. 2016;46(2):129\u201365.","journal-title":"Hepatol Res"},{"key":"1391_CR13","unstructured":"Viekirax tablets [package insert]. Tokyo, Japan: AbbVie Ltd; 2016."},{"key":"1391_CR14","unstructured":"Harvoni tablets [package insert]. Tokyo, Japan: Gilead Sciences; 2016."},{"issue":"1","key":"1391_CR15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.20984","volume":"43","author":"Y Iwasaki","year":"2006","unstructured":"Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology. 2006;43(1):54\u201363.","journal-title":"Hepatology"},{"key":"1391_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02558-16","author":"TI Ng","year":"2017","unstructured":"Ng TI, Krishnan P, Pilot-Matias T, et al. In vitro antiviral activity and resistance profile of the next generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother. 2017;. doi: 10.1128\/AAC.02558-16 .","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"1391_CR17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1053\/j.gastro.2016.07.020","volume":"151","author":"E Gane","year":"2016","unstructured":"Gane E, Poordad F, Wang S, et al. High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology. 2016;151(4):651\u20139 e1.","journal-title":"Gastroenterology"},{"issue":"2","key":"1391_CR18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","volume":"67","author":"PY Kwo","year":"2017","unstructured":"Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67(2):263\u201371.","journal-title":"J Hepatol"},{"key":"1391_CR19","doi-asserted-by":"crossref","unstructured":"Puoti M, Foster GR, Wang S, et al. High SVR rates with eight and twelve weeks of Pangenotypic Glecaprevir\/Pibrentasvir: integrated efficacy analysis of genotype 1-6 patients without Cirrhosis. European Association for the Study of the Liver: Amsterdam, Netherlands; 2017.","DOI":"10.1016\/S0016-5085(17)33577-1"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-017-1391-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-017-1391-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-017-1391-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T22:52:03Z","timestamp":1570143123000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-017-1391-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,25]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["1391"],"URL":"https:\/\/doi.org\/10.1007\/s00535-017-1391-5","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,25]]}}}